Investment
Features
FeesSafety
Academy
More
Pluang+

Hims & Hers Health upgraded to buy as GLP-1 drug sales exceed expectations, boosting growth outlook.

Analyst Insights
13 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Hims & Hers Health has been upgraded to a buy rating due to stronger-than-expected sales of its branded GLP-1 drug Wegovy, which shipped 125,000 units in six weeks. Management now expects over 100,000 monthly new weight-loss subscribers, restoring confidence in the company's growth prospects. Key concerns about the company's identity, growth drivers, and regulatory risks have eased, though margin compression remains a potential challenge. The upgrade depends on Hims & Hers maintaining support above $25, continuing Wegovy momentum, and stabilizing gross margins in the coming quarters.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App